The blood–brain barrier,TWEAK,and neuropsychiatric involvement in human systemic lupus erythematosus and primary Sjögren’s syndrome

Abstract

Objective

A prevailing hypothesis for neuropsychiatric involvement in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome is that brain reactive autoantibodies enter the brain through a disrupted blood–brain barrier. Our aim was to investigate whether TNF-like weak inducer of apoptosis (TWEAK) plays a role in cerebral involvement in human SLE and primary Sjögren’s syndrome, and whether an impaired blood–brain barrier is a prerequisite for neuropsychiatric manifestations.

Methods

TWEAK was measured in the cerebrospinal fluid and serum and compared with markers of blood–brain barrier permeability (Q-albumin and MRI contrast-enhanced lesions) and S100B, an astrocyte activation marker in 50 SLE and 52 primary Sjögren’s syndrome patients. Furthermore, we estimated the general intrathecal B-cell activation (IgG index), measured anti-NR2 antibodies in cerebrospinal fluid, and explored whether these variables were associated with neuropsychiatric manifestations.

Results

No associations were found between TWEAK in the cerebrospinal fluid or serum and neuropsychiatric manifestations in SLE nor in primary Sjögren’s syndrome patients. Furthermore, no associations were found between neuropsychiatric manifestations and indicators of blood–brain barrier integrity or astroglial activity. Anti-NR2 antibodies were associated with impaired visuospatial processing (odds ratio 4.9, P = 0.03) and motor functioning (odds ratio 6.0, P = 0.006).

Conclusion

No clinical neuropsychiatric manifestations could be attributed to impaired integrity of the blood–brain barrier, or to TWEAK levels in cerebrospinal fluid or serum in either patient group. The TWEAK concentration was considerably higher in the cerebrospinal fluid than in blood, which indicates intrathecal production. We hypothesize that increased TWEAK and S100B result from immunological stress caused by brain-reactive antibodies produced by brain residing immune cells.

Keywords

Neuropsychiatric lupus systemic lupus erythematosus Sjögren’s syndrome TWEAK blood–brain barrier autoantibodies

Get full access to this article

View all access options for this article.

References

Kowal

DeGiorgio

Nakaoka

et al.

Cognition and immunity; antibody impairs memory. Immunity 2004; 21: 179–188.

Omdal

Brokstad

Waterloo

et al.

Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392–398.

Matus

Burgos

Bravo-Zehnder

et al.

Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007; 204: 3221–3234.

Estiasari

Matsushita

Masaki

et al.

Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogren’s syndrome patients with central nervous system manifestations. Mult Scler 2012; 18: 807–816.

Lauvsnes

Maroni

Appenzeller

et al.

Memory dysfunction in primary Sjogren’s syndrome is associated with anti-NR2 antibodies. Arthritis Rheum 2013; 65: 3209–3217.

Banks

Erickson

. The blood–brain barrier and immune function and dysfunction. Neurobiol Dis 2010; 37: 26–32.

Abbott

Ronnback

Hansson

. Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006; 7: 41–53.

Wang

Bordey

. The astrocyte odyssey. Prog Neurobiol 2008; 86: 342–367.

Donato

Cannon

Sorci

et al.

Functions of S100 proteins. Curr Mol Med 2013; 13: 24–57.

10.

Bertheloot

Latz

. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol 2017; 14: 43–64.

11.

Michetti

Corvino

Geloso

et al.

The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem 2012; 120: 644–659.

12.

Smirniotopoulos

Murphy

Rushing

et al.

Patterns of contrast enhancement in the brain and meninges. Radiographics: a review publication of the Radiological Society of North America, Inc 2007; 27: 525–551.

13.

Kassner

Thornhill

. Measuring the integrity of the human blood–brain barrier using magnetic resonance imaging. Methods Mol Biol (Clifton, NJ) 2011; 686: 229–245.

14.

Polavarapu

Gongora

Winkles

et al.

Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci 2005; 25: 10094–10100.

15.

Yepes

. TWEAK and FN14 in central nervous system health and disease. Front Biosci: a journal and virtual library 2007; 12: 2772–2781.

16.

Winkles

. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411–425.

17.

Stock

Wen

Putterman

. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol 2013; 4: 484–484.

18.

Yepes

. TWEAK and Fn14 in the neurovascular unit. Front Immunol 2013; 4: 367–367.

19.

Stephan

Sbai

Wen

et al.

TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. J Neuroinflam 2013; 10: 9–9.

20.

Wen

Xia

Stock

et al.

Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun 2013; 43: 44–54.

21.

Wen

Doerner

Weidenheim

et al.

TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun 2015; 60: 40–50.

22.

Wicovsky

Salzmann

Roos

et al.

TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Different 2009; 16: 1445–1459.

23.

Echeverry

Haile

et al.

The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system. J Neuroinflam 2012; 9: 45–45.

24.

Boulamery

Desplat-Jego

. Regulation of neuroinflammation: what role for the tumor necrosis factor-like weak inducer of apoptosis/Fn14 pathway? Front Immunol 2017; 8: 1534–1534.

25.

Harboe

Tjensvoll

Maroni

et al.

Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis 2009; 68: 1541–1546.

26.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

27.

Vitali

Bombardieri

Jonsson

et al.

Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

28.

American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

29.

Grimstad

Skoie

Doerner

et al.

TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. Scand J Gastroenterol 2017; 52: 420–424.

30.

Scheltens

Barkhof

Leys

et al.

A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993; 114: 7–12.

31.

Fragoso-Loyo

Atisha-Fregoso

Nunez-Alvarez

et al.

Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erythematosus. Lupus 2016; 25: 364–369.

32.

Gulati

Iffland

PH II

Janigro

et al.

Anti-NR2 antibodies, blood–brain barrier, and cognitive dysfunction. Clin Rheumatol 2016; 35: 2989–2997.

33.

Korn

Kallies

. T cell responses in the central nervous system. Nat Rev Immunol 2017; 17: 179–194.

34.

Yoshio

Okamoto

Hirohata

et al.

IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum 2013; 65: 457–463.

35.

Ainiala

Loukkola

Peltola

et al.

The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496–500.

36.

Hanly

Urowitz

Sanchez-Guerrero

et al.

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56: 265–273.

37.

Hanly JG, Kozora E, Beyea S, et al. Nervous system disease in Systemic Lupus Erythematosus: current status and future directions. Arthritis Rheumatol (Hoboken, NJ). Epub ahead of print 22 June 2018. DOI: 10.1002/art.40591.

38.

Stock

Gelb

Pasternak

et al.

The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev 2017; 16: 612–619.